Zimmer Biomet Holdings ( (ZBH) ) has released its Q4 earnings. Here is a breakdown of the information Zimmer Biomet Holdings presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Zimmer Biomet Holdings, Inc., a leading player in the global medical technology sector, specializes in innovative products and integrated digital and robotic technologies aimed at improving mobility and health outcomes. The company is noted for its extensive portfolio that leverages data analytics and artificial intelligence.
In its latest financial report, Zimmer Biomet announced a positive end to the fiscal year 2024, with fourth quarter net sales reaching $2.023 billion, marking a 4.3% increase from the previous year. The company also reported full-year net sales of $7.679 billion, reflecting a growth of 3.8%. The full-year adjusted diluted earnings per share was recorded at $8.00, demonstrating robust financial health.
Key highlights of the report include a strategic move towards diversification with the acquisition of Paragon 28, Inc., enhancing the company’s presence in the foot and ankle orthopedic segment. The company also achieved significant regulatory milestones, such as the FDA Premarket Approval for the Oxford Cementless Partial Knee and the 510(k) clearance for the OsseoFit Stemless Shoulder System. Additionally, Zimmer Biomet’s S.E.T. category experienced notable growth, surpassing the Hip segment in its growth trajectory.
Looking forward, Zimmer Biomet has provided a financial guidance for 2025, projecting a constant currency revenue change of 3.0% to 5.0% and adjusted diluted EPS between $8.15 and $8.35. The company remains committed to its strategy of portfolio diversification and investment in high-growth markets, positioning itself to sustain its momentum in the medical technology industry.
